Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis

References

• Magliano DJ, Boyko EJ. IDF diabetes atlas 10th edition scientific committee. IDF DIABETES ATLAS [internet]. 10th ed. Brussels: International Diabetes Federation; 2021. Chapter 3, Global picture.
   Google Scholar
• Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107–111. doi: 10.2991/jegh.k.191028.001
   PubMed Web of Science ®Google Scholar
• Halvorsen RE, Elvestad M, Molin M, et al. Fruit and vegetable consumption and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of prospective studies. BMJ Nutr Prev Health. 2021;4:519–531. doi: 10.1136/bmjnph-2020-000218
   PubMedGoogle Scholar
• Moradi S, Hojjati Kermani MA, Bagheri R, et al. Ultra-processed Food consumption and adult diabetes risk: a systematic review and dose-response meta-analysis. Nutrients. 2021;13(12):4410. doi: 10.3390/nu13124410
   PubMed Web of Science ®Google Scholar
• Park JH, Moon JH, Kim HJ, et al. Sedentary lifestyle: overview of updated evidence of potential Health risks. Korean J Fam Med. 2020;41(6):365–373. doi: 10.4082/kjfm.20.0165
   PubMed Web of Science ®Google Scholar
• Schroeder EB. Management of type 2 diabetes: selecting amongst Available pharmacological agents. In: Feingold K, Anawalt B, and Blackman M, editors. Endotext [internet]. South Dartmouth (MA): MDText.com, Inc; 2000. https://www.ncbi.nlm.nih.gov/books/NBK425702/
   Google Scholar
• Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021;131(2):131. doi: 10.1172/JCI142243
   Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of Medical care in diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S125–S143. doi: 10.2337/dc22-S009
   PubMedGoogle Scholar
• Williams DM, Jones H, Stephens JW. Personalized type 2 diabetes management: an update on recent advances and recommendations. Diabetes Metab Syndr Obes. 2022;15:281–295. doi: 10.2147/DMSO.S331654
   PubMed Web of Science ®Google Scholar
• Yu J, Lee S-H, Kim MK. Recent updates to clinical practice guidelines for diabetes mellitus. Endocrinol Metab. 2022;37(1):26–37. doi: 10.3803/EnM.2022.105
   Google Scholar
• Sano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters: functional properties and pharmaceutical potential. J Diabetes Investig. 2020;11:770–782. doi: 10.1111/jdi.13255
   PubMed Web of Science ®Google Scholar
• Vallon V. Glucose transporters in the kidney in health and disease. Pflugers Arch - Eur J Physiol. 2020;472(9):1345–1370. doi: 10.1007/s00424-020-02361-w
   PubMed Web of Science ®Google Scholar
• Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020;8(2):8. doi: 10.3390/diseases8020014
   PubMedGoogle Scholar
• Shaffner J, Chen B, Malhotra DK, et al. Therapeutic targeting of SGLT2: a new era in the treatment of diabetes and diabetic kidney disease. Front Endocrinol. 2021;12:749010. doi: 10.3389/fendo.2021.749010
   PubMed Web of Science ®Google Scholar
• Niu Y, Liu R, Guan C, et al. Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter. Nature. 2022;601:280–284. doi: 10.1038/s41586-021-04212-9
   PubMed Web of Science ®Google Scholar
• Hoy SM. Bexagliflozin: first approval. Drugs. 2023;83:447–453.
   PubMedGoogle Scholar
• Zhang W, Welihinda A, Mechanic J, et al. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res. 2011;63:284–293. doi: 10.1016/j.phrs.2011.01.001
   PubMed Web of Science ®Google Scholar
• TheracosBio LLC BRENZAVVY (bexagliflozin) tablets, for oral use: US prescribing information. 2023 [cited 2023 May 19]. Available from: https://www.fda. gov/.
   Google Scholar
• Manoj A, Das S, Kunnath Ramachandran A, et al. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. Future Med Chem. 2020;12(21):1961–1990. doi: 10.4155/fmc-2020-0154
   PubMed Web of Science ®Google Scholar
• Halvorsen Y-D, Walford GA, Massaro J, et al. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diab Obes Metab. 2019;21:2496–2504. doi: 10.1111/dom.13833
   PubMed Web of Science ®Google Scholar
• Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19(12):1630–1641. doi: 10.1111/obr.12755
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:2099. doi: 10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:1801–1802. doi: 10.1056/NEJMoa1515920
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. doi: 10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74:790–799. doi: 10.1016/j.recesp.2021.06.016
   PubMed Web of Science ®Google Scholar
• McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55–61. doi: 10.1002/jrsm.1411
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. doi: 10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Debray TPA, Moons KGM, Riley RD. Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests. Res Synth Methods. 2018;9:41–50. doi: 10.1002/jrsm.1266
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration. Fixed or random effects?: Cochrane training Cochrane handbook for systematic reviews of Interventions. 2022 [ updated 2022; cited 2023 Jul 1]. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-10-4-1.
   Google Scholar
• Ahn E, Kang H. Introduction to systematic review and meta-analysis. Korean J Anesthes. 2018;71(2):103–112. doi: 10.4097/kjae.2018.71.2.103
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration. Heterogeneity: Cochrane Training Cochrane Handbook for Systematic Reviews of Interventions. 2022 [cited 2023 Jul 2]. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-10.
   Google Scholar
• Review Manager (RevMan) [computer program]. Version 5.4.1, the Cochrane collaboration. 2020 [cited 2022 May 29]. Available from: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download/download-and-installation.
   Google Scholar
• Lock JP Safety and efficacy of bexagliflozin as monotherapy in patients with type 2 diabetes. ClinicalTrials.Gov identifier: NCT02715258. Posted 2016 Mar 22; cited 2023 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02715258.
   Google Scholar
• Lock JP. Bexagliflozin efficacy and safety trial (BEST). ClinicalTrials. gov identifier: NCT02558296. Posted 2015 Sep 23; cited 2023 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02558296.
   Google Scholar
• Halvorsen Y-D, Walford G, Thurber T, et al. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diab Obes Metab. 2020;22(4):566–573. doi: 10.1111/dom.13928
   PubMed Web of Science ®Google Scholar
• Allegretti AS, Zhang W, Zhou W, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 2019;74(3):328–337. doi: 10.1053/j.ajkd.2019.03.417
   PubMed Web of Science ®Google Scholar
• Lock JP Safety and efficacy of bexagliflozin compared to placebo as add-on therapy to metformin in type 2 diabetes subjects. Clinical- Trials.Gov Identifier: NCT03259789. [ Posted 2017 Aug 24; cited 2023 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT03259789.
   Google Scholar
• Halvorsen Y-D, Lock JP, Zhou W, et al. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diab Obes Metab. 2019;21(10):2248–2256. doi: 10.1111/dom.13801
   PubMed Web of Science ®Google Scholar
• Lock JP Safety and efficacy of bexagliflozin compared to glimepiride as add-on therapy to metformin in type 2 diabetes subjects. Clinical- Trials.Gov Identifier: NCT02769481. [ Posted 2016 May 11; cited 2023 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02769481.
   Google Scholar
• Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525–539. doi: 10.1038/s41574-022-00690-7
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of Medical care in diabetes-2021. Diabetes Care. 2021; 44:S73–S84. doi: 10.2337/dc21-S006
   PubMed Web of Science ®Google Scholar
• Zhang W, Li X, Ding H, et al. Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans. Xenobiotica. 2020;50(5):559–569. doi: 10.1080/00498254.2019.1654634
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62:3324–3328. doi: 10.2337/db13-0604
   PubMed Web of Science ®Google Scholar
• Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diabetes Metab Syndr Obes. 2020;13:161–174. doi: 10.2147/DMSO.S233538
   PubMed Web of Science ®Google Scholar
• Lock JP Safety and efficacy of bexagliflozin in subjects with moderate hepatic impairment. ClinicalTrials. gov identifier: NCT03557658. [cited 2018 Jun 15]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT0355765.
   Google Scholar
• Freeman M Study to evaluate effects of probenecid, rifampin and verapamil on bexagliflozin in healthy subjects. ClinicalTrials. gov identifier: NCT03296800. [cited 2017 Sep 28]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03296800.
   Google Scholar
• Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5:169–179. doi: 10.1016/j.jacbts.2019.11.007
   PubMedGoogle Scholar
• Kawasoe S, Maruguchi Y, Kajiya S, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017;18(1):23. doi: 10.1186/s40360-017-0125-x
   PubMed Web of Science ®Google Scholar
• Darenskaya MA, Kolesnikova LI, Kolesnikov SI. Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction. Bull Exp Biol Med. 2021;171(2):179–189. doi: 10.1007/s10517-021-05191-7
   PubMed Web of Science ®Google Scholar
• Patoulias D, Dimosiari A. Meta-analysis addressing the cardiovascular safety of bexagliflozin in patients with type 2 diabetes mellitus. Am J Cardiol. 2022;178:178–179. doi: 10.1016/j.amjcard.2022.05.005
   PubMed Web of Science ®Google Scholar
• Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019;20(3):20. doi: 10.3390/ijms20030629
   Web of Science ®Google Scholar
• Eberly LA, Yang L, Eneanya ND, et al. Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021;4(4):e216139. doi: 10.1001/jamanetworkopen.2021.6139
   PubMed Web of Science ®Google Scholar
• Rådholm K, Zhou Z, Clemens K, et al. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diab Obes Metab. 2020;22(2):263–266. doi: 10.1111/dom.13876
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane: Wiley; 2022. Available from: www.training.cochrane.org/handbook.
   Google Scholar